> Back to EJC

Recent editions

  • September 2014
    Discussing how healthcare systems can meet the needs of cancer survivors.
  • July/August 2014
    Sophie Postel-Vinay on new recommendations for phase 1 trials.
  • June 2014
    Hans Clevers on important research into stem cells in normal gut tissue.
  • May 2014
    Carolyn Taylor and Paul McGale find evidence to clarify guidelines for radiotherapy after mastectomy.
  • April 2014
    Richard Sullivan and Ajay Aggarwal on how physicians can tackle the issue of affordability in cancer care.
  • March 2014
    The 1st EORTC Cancer Survivorship Summit addressed the practical problems faced by cancer patients.
  • February 2014
    Charles Swanton on a study that maps genetic changes in cancers over time.
  • January 2014
    Presidents of various cancer societies make predictions for the coming year.
  • December 2013
    Precision diagnostics have great potential, but changes are needed to make them more available.
  • November 2013
    Highlights of the European Cancer Congress - cancer society presidents give their view.
  • October 2013
    Richard Schilsky on the changes needed as personalised medicine enters the clinic.
  • September 2013
    A new advance in immunotherapy is discussed by Jean-Charles Soria and Caroline Robert.

> All 2013 Editions

> All 2012 Editions

> All 2011 Editions

 

EJC News Focus – July/August 2013

Loading EJC News Focus video

Good times and bad for clinical trials research

Functional imaging and other new technologies are revolutionising the landscape for cancer research. The knowledge imparted by these techniques – from genetics, epigenetics, proteomics and so on – should mean that we're entering a new phase in our understanding and therefore treatment of the disease.

Yet many of the same old obstacles between lab and clinic remain. Clinical trials research is still dogged by regulatory issues, funding is a perennial problem, agreement on data protection has yet to be reached.

EORTC President Roger Stupp calls for the patient's point of view to move centre stage. While rarified discussions and debates take place, patients are waiting for clinical trials to be set up and for results to be integrated into clinical practice, he says. Here, he tells Helen Saul that speedy activation of trials is needed, as is funding for academic trials and, overall, a common sense approach which would allow the questions most relevant to patients, to be addressed.